Cadrenal Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for patients with chronic kidney disease and related disorders
The company is committed to advancing innovative treatment options that address unmet medical needs in the renal space, leveraging its expertise in drug development and research to create transformative solutions. Cadrenal aims to improve the quality of life for patients through its targeted approaches to disease management and therapeutic interventions, and is dedicated to clinical research that fosters a deeper understanding of kidney health.
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD.
Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% to $0.6050 in pre-market trading
Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.
